176 related articles for article (PubMed ID: 27750031)
21. Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase IIalpha promoter.
Flores LV; Staples AM; Mackay H; Howard CM; Uthe PB; Sexton JS; Buchmueller KL; Wilson WD; O'Hare C; Kluza J; Hochhauser D; Hartley JA; Lee M
Chembiochem; 2006 Nov; 7(11):1722-9. PubMed ID: 16991167
[TBL] [Abstract][Full Text] [Related]
22. β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells.
Gong M; Liu Y; Zhang J; Gao YJ; Zhai PP; Su X; Li X; Li Y; Hou L; Cui XN
Biomed Res Int; 2015; 2015():153987. PubMed ID: 26221582
[TBL] [Abstract][Full Text] [Related]
23. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
24. Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
Ernst AI; Soltermann A; Sigrist JA; Widmer L; Gasser SM; Stahel RA
Int J Cancer; 2000 Oct; 88(1):99-107. PubMed ID: 10962446
[TBL] [Abstract][Full Text] [Related]
25. UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.
Mann MJ; Pereira ER; Liao N; Hendershot LM
PLoS One; 2012; 7(10):e47931. PubMed ID: 23144714
[TBL] [Abstract][Full Text] [Related]
26. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
27. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
[TBL] [Abstract][Full Text] [Related]
28. CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase IIalpha. Conventional CBF activation domains are not required.
Hu Q; Bhattacharya C; Maity SN
J Biol Chem; 2002 Oct; 277(40):37191-200. PubMed ID: 12149265
[TBL] [Abstract][Full Text] [Related]
29. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells.
Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD
Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051
[TBL] [Abstract][Full Text] [Related]
30. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
31. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
32. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells.
Hong Y; Sang M; Shang C; Xue YX; Liu YH
Neurosci Lett; 2012 Jun; 518(2):138-43. PubMed ID: 22569122
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
36. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs.
Tolner B; Hartley JA; Hochhauser D
Mol Pharmacol; 2001 Apr; 59(4):699-706. PubMed ID: 11259613
[TBL] [Abstract][Full Text] [Related]
38. Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity.
Emanuelli A; Borroni AP; Apel-Sarid L; Shah PA; Ayyathan DM; Koganti P; Levy-Cohen G; Blank M
Cancer Res; 2017 Aug; 77(16):4217-4227. PubMed ID: 28611047
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Qi X; Hou S; Lepp A; Li R; Basir Z; Lou Z; Chen G
J Biol Chem; 2011 Oct; 286(41):35883-35890. PubMed ID: 21878638
[TBL] [Abstract][Full Text] [Related]
40. 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
Mensah-Osman EJ; Al-Katib AM; Wu HY; Osman NI; Mohammad RM
Mol Cancer Ther; 2002 Dec; 1(14):1321-6. PubMed ID: 12516965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
